Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

BACKGROUND: Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient outcomes during vedolizumab treatment in UC. METHODS: Prospectively scored maintenance clinical (26.5 weeks; interquar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Inflamm Bowel Dis
Main Authors: Battat, Robert, Dulai, Parambir S, Vande Casteele, Niels, Evans, Elisabeth, Hester, Kelly D, Webster, Edvelyn, Jain, Anjali, Proudfoot, James A, Mairalles, Ara, Neill, Jennifer, Singh, Siddharth, Chang, John T, Rivera-Nieves, Jesus, Sandborn, William J, Boland, Brigid S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Future Directions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6327228/
https://ncbi.nlm.nih.gov/pubmed/30295781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados